bluebird bio, Inc. Stock News

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird” or “the Company”) today announced that after three weeks of engagement, including a timeline extension, Ayrmid Ltd. (“Ayrmid”) has not submitted a binding proposal to acquire bluebird and has not obtained necessary financing. In consultation with its financial and legal advisors, the bluebird Board of Directors (t...

Gene therapy maker bluebird bio said on Friday it had received a non-binding offer from peer Ayrmid for up to $110.5 million, sending its shares up 9.8% at $4.40 in extended trading.

Bluebird Bio has received a competing bid from Ayrmid to buy the cash-strapped gene-therapy company in a deal potentially valued at up to $110.5 million.

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird”) today confirmed it has received an unsolicited non-binding written proposal (the “Ayrmid Proposal”) from Ayrmid Ltd (“Ayrmid”) to acquire bluebird for an upfront cash payment of $4.50 per share and a one-time contingent value right of $6.84 per share payable upon achievement of a net sales milestone. As previousl...

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of bluebird bio, Inc. (NasdaqGS: BLUE) to Carlyle Group and SK Capital Partners, LP. Under the terms of the agreement, bluebird shareholders will receive $3.00 per share in cash and a contingent value righ...

PHILADELPHIA, PA / ACCESS Newswire / March 12, 2025 / Kehoe Law Firm, P.C. continues its investigation on behalf of investors of bluebird bio (NASDAQ:BLUE) regarding the adequacy and fairness of the proposed acquisition of bluebird bio by "funds managed by global investment firms Carlyle (NASDAQ: CG) and SK Capital Partners, LP ("SK Capital") in collaboration with a team of highly experienced b...

NEW YORK CITY, NY / ACCESS Newswire / March 5, 2025 / Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of bluebird bio, Inc. (NASDAQ:BLUE) to Carlyle Group and SK Capital Partners, LP is fair to bluebird shareholders. Under the terms of the agreement, bluebird shareholders will receive $3.00 per share in cash and a contingent value right per share, entitling the ...

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of bluebird bio, Inc. (NasdaqGS: BLUE) to Carlyle Group and SK Capital Partners, LP. Under the terms of the agreement, bluebird shareholders will receive $3.00 per share in cash and a contingent value right per share...